Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-06-12

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for buprenorphine and naloxone from Mylan Pharmaceuticals Inc. The approval updates the product's labeling/attribute…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)